Literature DB >> 16939808

Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells.

Jeffrey R Keefer1, Tonya A Schneidereith, Abbie Mays, Shirley H Purvis, George J Dover, Kirby D Smith.   

Abstract

OBJECTIVE: In vivo, several drugs have been shown to increase fetal hemoglobin (HbF), including 5-azacytidine (AZA), sodium butyrate (SB), and hydroxyurea (HU). Studies in K562 cells suggest that cyclic guanosine monophosphate (cGMP) is required for HbF induction; however, the role of cyclic nucleotides in HbF induction in primary erythroid cultures has not been established.
METHODS: CD34-selected peripheral blood monocytes cultured in a semi-solid serum-free system that mimics in vivo F-cell production are utilized to explore the role of cyclic adenosine monophosphate (cAMP) and cGMP in HbF induction in response to HU, AZA, and SB.
RESULTS: In serum-free CD34 cultures, HU, SB, and AZA all markedly stimulate FNRBC production up to 30-fold, associated with induction of gamma-globin mRNA and total HbF protein. Guanylate cyclase inhibition results in only minimal blunting of HbF induction by each agent. In contrast, adenylate cyclase inhibition markedly reduces HU, SB, and AZA-mediated FNRBC induction and gamma-globin mRNA induction. The adenylate cyclase activator forskolin modestly induces FNRBC production and augments the action of standard induction agents. HU, AZA, and SB, however, fail to significantly stimulate adenylate cyclase themselves.
CONCLUSIONS: In human CD34(+) cultures, cAMP production is required for full induction of HbF by HU, SB, and AZA, while perturbation of cGMP production has only minimal effects. These findings are in marked contrast to data in K562 cells where cGMP production is critical for HbF induction while cAMP stimulation blunts HbF response, and suggest that these agents may share a common induction pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939808     DOI: 10.1016/j.exphem.2006.03.018

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  18 in total

Review 1.  Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease.

Authors:  Betty S Pace; Li Liu; Biaoru Li; Levi H Makala
Journal:  Exp Biol Med (Maywood)       Date:  2015-08

2.  Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives.

Authors:  Natarajan V Bhanu; Y Terry Lee; Patricia A Oneal; Nicole M Gantt; Wulin Aerbajinai; Pierre Noel; Craig J Thomas; Jeffery L Miller
Journal:  Biochim Biophys Acta       Date:  2008-06-30

Review 3.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

4.  Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.

Authors:  Aisha L Walker; Shirley Steward; Thad A Howard; Nicole Mortier; Matthew Smeltzer; Yong-Dong Wang; Russell E Ware
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

5.  Krüppel-like factor 2 regulated gene expression in mouse embryonic yolk sac erythroid cells.

Authors:  Latasha C Redmond; Catherine I Dumur; Kellie J Archer; Dennis R Grayson; Jack L Haar; Joyce A Lloyd
Journal:  Blood Cells Mol Dis       Date:  2011-04-29       Impact factor: 3.039

6.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.

Authors:  Vladan P Cokic; Silvana A Andric; Stanko S Stojilkovic; Constance T Noguchi; Alan N Schechter
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

7.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

8.  Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells.

Authors:  Himanshu Bhatia; Jennifer L Hallock; Amrita Dutta; Shay Karkashon; Lauren S Sterner; Toru Miyazaki; Ann Dean; Jane A Little
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

9.  Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin.

Authors:  Rodwell Mabaera; Michael R Greene; Christine A Richardson; Sarah J Conine; Courtney D Kozul; Christopher H Lowrey
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

10.  Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.

Authors:  Danilo Grunig Humberto Silva; Edis Belini Junior; Gisele Cristine de Souza Carrocini; Lidiane de Souza Torres; Octávio Ricci Júnior; Clarisse Lopes de Castro Lobo; Claudia Regina Bonini-Domingos; Eduardo Alves de Almeida
Journal:  BMC Med Genet       Date:  2013-10-09       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.